AU2019391300B2 - Modified GIP peptide analogues - Google Patents

Modified GIP peptide analogues Download PDF

Info

Publication number
AU2019391300B2
AU2019391300B2 AU2019391300A AU2019391300A AU2019391300B2 AU 2019391300 B2 AU2019391300 B2 AU 2019391300B2 AU 2019391300 A AU2019391300 A AU 2019391300A AU 2019391300 A AU2019391300 A AU 2019391300A AU 2019391300 B2 AU2019391300 B2 AU 2019391300B2
Authority
AU
Australia
Prior art keywords
gip
seq
amino acid
peptide
diacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019391300A
Other languages
English (en)
Other versions
AU2019391300A1 (en
Inventor
Ditte Riber
Mette Marie Rosenkilde
Bjørn Behrens SIVERTSEN
Alexander Hovard SPARRE-ULRICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antag Therapeutics Aps
Original Assignee
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antag Therapeutics Aps filed Critical Antag Therapeutics Aps
Publication of AU2019391300A1 publication Critical patent/AU2019391300A1/en
Application granted granted Critical
Publication of AU2019391300B2 publication Critical patent/AU2019391300B2/en
Priority to AU2025237957A priority Critical patent/AU2025237957A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019391300A 2018-12-03 2019-12-03 Modified GIP peptide analogues Active AU2019391300B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025237957A AU2025237957A1 (en) 2018-12-03 2025-09-24 Modified GIP peptide analogues

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18209896.2 2018-12-03
EP18209896 2018-12-03
EP19176739.1 2019-05-27
EP19176739 2019-05-27
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025237957A Division AU2025237957A1 (en) 2018-12-03 2025-09-24 Modified GIP peptide analogues

Publications (2)

Publication Number Publication Date
AU2019391300A1 AU2019391300A1 (en) 2021-07-01
AU2019391300B2 true AU2019391300B2 (en) 2025-06-26

Family

ID=68731999

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019391300A Active AU2019391300B2 (en) 2018-12-03 2019-12-03 Modified GIP peptide analogues
AU2025237957A Pending AU2025237957A1 (en) 2018-12-03 2025-09-24 Modified GIP peptide analogues

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025237957A Pending AU2025237957A1 (en) 2018-12-03 2025-09-24 Modified GIP peptide analogues

Country Status (11)

Country Link
US (3) US12187773B2 (enExample)
EP (2) EP3891173A1 (enExample)
JP (1) JP7605747B2 (enExample)
CN (1) CN113366014B (enExample)
AU (2) AU2019391300B2 (enExample)
BR (1) BR112021010447A2 (enExample)
CA (1) CA3121043A1 (enExample)
IL (1) IL283385A (enExample)
MX (1) MX2021006505A (enExample)
SG (1) SG11202105586YA (enExample)
WO (2) WO2020115048A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250346647A2 (en) * 2019-12-03 2025-11-13 Antag Therapeutics Aps Optimized GIP Peptide Analogues
CN116133677A (zh) * 2020-07-06 2023-05-16 鸿绪生物医药科技（北京）有限公司 新型多肽制剂及其治疗用途
CA3185229A1 (en) * 2020-07-06 2022-01-13 Jie Han Novel polypeptide and therapeutic use thereof
IL304214B2 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc Compositions and methods for treating metabolic and liver disorders
BR112023024968A2 (pt) * 2021-06-10 2024-02-20 Antag Therapeutics Aps Tratamento da obesidade e distúrbios relacionados à obesidade
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
JP2025523681A (ja) * 2022-07-13 2025-07-23 杭州中美華東製薬有限公司 Ｇｌｐ－１／ｇｉｐ二重アゴニスト、その調製方法および使用
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
WO2024209050A1 (en) * 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034186A1 (en) * 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5745335A (en) 1996-06-27 1998-04-28 Gennum Corporation Multi-layer film capacitor structures and method
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
CZ297361B6 (cs) 1998-01-30 2006-11-15 Novo Nordisk A/S Injekcní stríkacka
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
WO2000020592A1 (en) 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
DE69922043T2 (de) 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE60012721D1 (de) 1999-03-29 2004-09-09 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
DE60216629T2 (de) 2001-09-21 2007-10-11 Koninklijke Philips Electronics N.V. Gibt es kein spezifisches kontrollmodul? benutzen sie eines das weniger spezifisch ist
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2006213607A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
MX2011001032A (es) 2008-08-07 2011-08-12 Ipsen Pharma Sas Analogos polipeptidos de insulinotropicos dependientes de glucosa (gip) modificados en n terminal.
ES2574835T3 (es) 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
KR20110043686A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
DK2320923T3 (en) 2008-08-07 2015-03-02 Ipsen Pharma Sas Truncated analogues of glucose-dependent insulinotropic polypeptide
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US8975223B2 (en) 2010-12-22 2015-03-10 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
JP5914641B2 (ja) * 2011-06-10 2016-05-11 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用
US9340600B2 (en) * 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
EP3556399A1 (en) * 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
WO2018124010A1 (ja) 2016-12-26 2018-07-05 花王株式会社 認知機能改善剤
CN110099694A (zh) 2016-12-26 2019-08-06 花王株式会社 低体温改善剂
CN110139672A (zh) 2016-12-26 2019-08-16 花王株式会社 运动调节功能提高剂
PL3630806T3 (pl) * 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034186A1 (en) * 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pathak, V., et al. "Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N-and C-terminal modifications improves obesity and metabolic control in high fat fed mice."Mol.Cell.Endocrinol. (2015): 120-129. *

Also Published As

Publication number Publication date
US20220298218A1 (en) 2022-09-22
AU2025237957A1 (en) 2025-10-16
US20250376499A1 (en) 2025-12-11
BR112021010447A2 (pt) 2021-08-24
MX2021006505A (es) 2021-10-01
KR20210102911A (ko) 2021-08-20
CA3121043A1 (en) 2020-06-11
WO2020115049A1 (en) 2020-06-11
SG11202105586YA (en) 2021-06-29
CN113366014A (zh) 2021-09-07
JP2022509568A (ja) 2022-01-20
CN113366014B (zh) 2025-10-21
EP3891173A1 (en) 2021-10-13
US20220025010A1 (en) 2022-01-27
JP7605747B2 (ja) 2024-12-24
US12187773B2 (en) 2025-01-07
US12297250B2 (en) 2025-05-13
AU2019391300A1 (en) 2021-07-01
WO2020115048A1 (en) 2020-06-11
EP3891174A1 (en) 2021-10-13
IL283385A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
AU2019391300B2 (en) Modified GIP peptide analogues
CN111491658A (zh) 肠促胰岛素类似物及其用途
CN102573888A (zh) 长效y2 受体激动剂
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
CN114787183A (zh) 肠促胰岛素类似物及其用途
US11572399B2 (en) Long-acting GIP peptide analogues
CN111094331B (zh) 酰化胃泌酸调节素肽类似物
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
KR102906485B1 (ko) 변형된 gip 펩티드 유사체
CA3064510C (en) Long-acting gip peptide analogues

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)